Heart Rhythm
Volume 7, Issue 1 , Pages 9-14, January 2010

Incidence and predictors of mortality following ablation of ventricular tachycardia in patients with an implantable cardioverter-defibrillator

  • William H. Sauer, MD, FHRS

      Affiliations

    • Electrophysiology Section, Cardiovascular Division, Department of Medicine, University of Colorado, Aurora, Colorado
  • ,
  • Erica Zado, PA-C

      Affiliations

    • Electrophysiology Section, Cardiovascular Division, Department of Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania
  • ,
  • Edward P. Gerstenfeld, MD

      Affiliations

    • Electrophysiology Section, Cardiovascular Division, Department of Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania
  • ,
  • Francis E. Marchlinski, MD, FHRS

      Affiliations

    • Electrophysiology Section, Cardiovascular Division, Department of Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania
  • ,
  • David J. Callans, MD, FHRS

      Affiliations

    • Electrophysiology Section, Cardiovascular Division, Department of Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania
    • Corresponding Author InformationAddress reprint requests and correspondence: Dr. David J. Callans, Section of Cardiac Electrophysiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, Pennsylvania 19104

Received 10 July 2009; accepted 7 September 2009. published online 14 September 2009.

Background

Long-term outcomes following ablation of ventricular tachycardia (VT) have not been well described.

Objective

The purpose of this study was to identify the incidence and predictors of mortality following catheter ablation of VT in patients with an implantable cardioverter-defibrillator (ICD).

Methods

The cohort included in the analysis consisted of patients with ischemic or nonischemic cardiomyopathy undergoing electrophysiologic study and ablation of VT. Catheter ablation of VT involved the use of pacemapping, entrainment mapping (when possible), and substrate modification. Clinical recurrences, ICD therapy history, and mortality were recorded for all patients included in the cohort. Comparisons were made between those subjects who died over a 3-year follow-up period and those who survived.

Results

A total of 208 subjects underwent 327 VT ablations over the course of the study period. Sixty-seven deaths (75% of all deaths and 32% of the cohort) occurred within 3 years after VT ablation. After multivariable adjustment, clinical predictors of mortality included age, lower left ventricular ejection fraction, and presence of renal insufficiency. Procedural variables associated with reduced mortality following VT ablation included presence of hemodynamically tolerated VT, lack of inducibilty of any VT following ablation, and procedural date in the latter part of the study.

Conclusion

The survival rate after VT ablation has improved over time and may reflect improved mapping and ablation techniques, in addition to improved therapies for treatment of congestive heart failure. Tolerated VT and lack of inducible ventricular arrhythmias following VT ablation was associated with improved survival in this study, suggesting their value as a risk factor for subsequent mortality.

Keywords: Ablation, Mortality, Ventricular tachycardia

Abbreviations: CI, confidence interval, ICD, implantable cardioverter-defibrillator, VT, ventricular tachycardia

 

 Drs. Marchlinski, Callans, and Gerstenfeld have received research funding support from St. Jude Medical and Biosense-Webster, Inc., manufacturers of ablation and mapping equipment. Drs. Marchlinski and Callans have received honoraria from Biosense-Webster.

PII: S1547-5271(09)01001-7

doi:10.1016/j.hrthm.2009.09.014

Heart Rhythm
Volume 7, Issue 1 , Pages 9-14, January 2010